Skip to main content
Caplight Logo









FNCT Biotech

FNCT Biotech

Private
South KoreaHealthcare & Life Scienceshttps://fnctbiotech.com/

Last Round

Series B

Jun 16, 2026

Total Funding Raised

$18.15M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

FNCT Biotech is a biotechnology company that develops first-in-class antibody therapeutics for diseases with high unmet medical needs, particularly Idiopathic Pulmonary Fibrosis (IPF) and various cancers.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Revenue Share, Services & Consulting, Government Contracts

AI Layer

Non-AI

Keywords

antibody therapeuticsIdiopathic Pulmonary FibrosisIPFmonoclonal antibodymAbsfirst-in-class therapeuticspreclinical biotechCSF3 targetbiotech out-licensinganti-fibrotic therapynovel drug targetdrug discoveryantibody discovery platformunmet medical needoncology therapeutics

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

FNCT Biotech Comparables

Compare FNCT Biotech with similar companies based on industry and business-model similarity.

FNCT Biotech comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Pulmongene
80%
PureTech Health
76%
Oorja Bio, Inc.
75%

FNCT Biotech Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BJun 16, 2026
Series AJan 20, 2025
SeedJul 1, 2022

Key People

Founding team and executive leadership

Lee Su-Jae

Chief Executive Officer

Executive Team

FNCT Biotech Investors

Notable investors and investment history

FNCT Biotech investors
InvestorRounds
DAYLI PartnersSeed
Premier PartnersSeries B
BSK InvestmentSeries B
IBK CapitalSeries B
NICE Investment PartnersSeries B
NH Nonghyup BankSeries B
Solidus InvestmentSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Sep 11, 2026

    Monthly visitors increased 1280% MoM.

  • Jun 16, 2026

    $14M round led by Premier Partners

FNCT Biotech Filings

Explore SEC and related filing metadata, where available.

FNCT Biotech filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about FNCT Biotech's valuation, stock price, and market status.

Is FNCT Biotech a public or private company?

FNCT Biotech is a private company.

What is the current stock price of FNCT Biotech?

FNCT Biotech is a private company, so its shares have no public market price. Caplight tracks FNCT Biotech's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.

How much is FNCT Biotech worth (valuation)?

Valuation information for FNCT Biotech is not publicly available.

Can I buy FNCT Biotech stock?

FNCT Biotech shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.

When was FNCT Biotech's last funding round?

FNCT Biotech's most recent funding round was Series B on June 16, 2026.

Who are the main investors in FNCT Biotech?

Key investors in FNCT Biotech include Premier Partners.

Will FNCT Biotech IPO soon?

No public IPO plans have been announced for FNCT Biotech.

How can I track FNCT Biotech secondary market activity?

Caplight tracks bids, offers, and trades in FNCT Biotech's shares on secondary markets.

Firmographic Details

HeadquartersSouth Korea
Employee Range3
Year Founded2021
Last FundingJun 16, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?